Why is AGIO down?
Down 17% from Oct 28 to Nov 13 while the S&P 500 fell 2%.
- Agios Pharmaceuticals fell 17% from Oct 28 to Nov 13. It fell 18% on Oct 30 alone.
Down 17% from Oct 28 to Nov 13 while the S&P 500 fell 2%.
Follow AGIO's trial news. Pro members can get an alert when Agios Pharmaceuticals files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Since its 2024 high | Down 48% |
| Latest filing | 8-K, Nov 5 |
Sat Dec 12: American Society of Hematology…Industry event · date confirmed.
Expected to report Thu Feb 18, before the open
About 10 quarters
Chief Medical Officer Sarah Gheuens sold 7,866 shares on Oct 26, under a planned sale. 18 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Below Averagefor quality, not price, 3 of 14 chart checks firingWhat the Quality Score means
AGIO is #99 of 270 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 99 |
Share count against a year before: AGIO +2.7%, INO +89%, MLYS +26%, SVRA +17%.
Expected to report Thu Feb 18, before the open (in 94 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $55.4M, 330% more than a year ago; a loss of $1.09 a share, from $1.78.
“This growth was driven by the U.S. commercial launch of AQVESME in thalassemia, where broadening demand is translating into a durable base of patients on therapy,”
| Line | Q3 2026 | Q2 2026 | Q3 2025 |
|---|---|---|---|
| United States | $48.7M | $40.9M | $12.3M |
Each quarter's sales and their share of its total. Figures as filed (SEC filing, Nov 5)
No outlook figures read from this release.
“Research and Development (R&D) expenses were $73.5 million for the third quarter of 2026, compared to $86.8 million for the third quarter of 2025, driven primarily by reductions in spend associated with mitapivat and tebapivat process development and certain clinical trials.”
From its results filing (SEC filing · Nov 5)
Its share count fell 3.4% a year over 5 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 5, 2026 | -0.6% | -9.9% | +4.6% |
| Jul 30, 2026 | -15.8% | -6.5% | -9.4% |
| Apr 29, 2026 | +6.8% | +13.1% | +9.7% |
Sales grew in five of the last seven years, to $54M in 2025. It lost money in 2025 after a profit in 2024.
RSI 46.3, MACD below signal, below both averages. Not scored.
No insider bought or sold AGIO in the last six months outside a trading plan. All 3 insider sales in the last three months were made under plans set up in advance, which the score leaves out.
One trade disclosed in the last six months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: AGIO is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
“The pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products.”
AGIO scores 2 today, which Breakaway calls Below Average. It is #99 of 270 in Biotech by Quality Score, with 3 of 14 chart checks firing. Down 17% from Oct 28 to Nov 13 while the S&P 500 fell 2%. Cash lasts about 10 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
AGIO scores 2 today, which Breakaway calls Below Average (0 to 5). That is #99 of 270 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind AGIO's 2.
Expected to report Thu Feb 18, before the open, a date Breakaway expects from the company's usual timing; the company has not confirmed it. AGIO closed higher after 2 of its last 4 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.Then 7 days of Pro free, with a card.